

\* 楊再勝醫師

所有發表期刊論文

1. Yang TS, Ng KT, Wang HM, Kiu MC, Wang CH, Lai GM: Combination chemotherapy with BCNU, Cisplatin, DTIC plus Tamoxifen for Metastatic malignant melanoma *J. Chinese Onco. Soc.* 9(4): 18-24, 1993
2. Kiu MC, Liaw CC, Yang TS, Lai GM, Hsi SN, Lu CS: Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma *Anti-Cancer Drugs* 5: 480-482, 1994
3. Kiu MC, Chang CN, Cheng WC, Lin TK, Wong CW, Tang SG, Leung WM, Chen LH, Ho YS, Ng KT, Chen JS, Yang TS, Lai GM: Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas *J of Neuro-Oncology* 25: 215-220, 1995
4. Ng SH, Ko SF, Yang TS, Wong HF, Wan YL, Ho YS: Primary cardiac chondrosarcoma *Am J of Em Med* 14:285-287, 1996
5. Yang TS, Ng KT, Wang HM, Wang CH, Liaw CC, Lai GM: Prognostic factors of locoregionally recurrent nasopharyngeal carcinoma--A retrospective review of 182 cases *Am J Clin Oncol* 19(4): 337-343, 1996
6. Liau CT, Yang TS, Wang CH, Hsueh S: Intra-abdominal desmoplastic small cell tumors-- report of two case *Anti-Cancer Drugs* 7: 228-232, 1996
7. Yang TS, Hsu KC, Chiang JM, Tang R, Chen JS, Changchien CR, Wang JY.: A simplified regimen of weekly high-dose 5-fluorouracil and leucovorin 24-hour infusion in patients with advanced colorectal cancer. *Cancer* 85: 1925-1930, 1999
8. Liaw CC, Wang HM, Wang CH, Yang TS, Chen JS, Chang HK, Lin YC, Liaw SH, Yeh CT. Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. *Anti-cancer drugs* 10:275-281, 1999
9. Chen JS, Liu HE, Wang CH, Yang TS, Wang HM, Liau CT, Chang WC, Lin YC.: Weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced gastric cancer. *Anti-cancer drugs* 10: 355-359, 1999
10. Lin YC, Liu HE, Wang CH, Wang HM, Yang TS, Liau CH, Chen JS.: Clinical benefit and response in patients with gastric cancer to weekly 24-hour infusion of high-dose 5-fluorouracil(5-FU) and leucovorin(LV). *Anti-cancer Res* 19: 5615-5620, 1999
11. Yeow KM, Wang CH, Liao TH, Chen JS, Wu JH, Yang TS, Wang PN. The

- Groshong Peripheral Inserted Central (PIC) Catheter: Initial Experience with Ultrasound-guided Insertion. *Chin J Radiol* 24(2) : 61-66, 1999
12. **Yang TS**, Hsu KC, Tang R, Chang TC: Colon carcinoma with synchronous ovarian metastasis—Report and discussion of five cases. *Anti-cancer drugs* 11: 279-293, 2000
  13. **Yang TS**, Lin YC, Chen JS, Wang HM, Wang CH: Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. *Cancer* 89: 750-6; 2000
  14. Wang HM, Ng SH, Wang CH, Liaw CT, Chen JS, **Yang TS**, Chen IH: Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa. *Anti-cancer drugs*: 12:331-337; 2001
  15. **Yang TS**, Hsu KC, Wang HM, Lin YC. Phase II study of a weekly 8-hour 5-fluorouracil and leucovorin infusion for patients with advanced colorectal cancer --- dose adjusted according to its toxicity. *Jpn J Clin Oncol* 31(12):610-615; 2001
  16. Lin YC, Chen JS, Wang CH, Wang HM, Chang HK, Liau CT, **Yang TS**, Liaw CC, Liu HE. Weekly high-dose 5-fluorouracil (5-FU), leucovorin (LV) and bimonthly cisplatin in patients with advanced gastric cancer. *Jpn J Clin Oncol* 31 (12): 605-609; 2001
  17. **Yang TS**, Wang JY, Tang R, Hsu KC, Chen JS. Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer. *Jpn J Clin Oncol* 32(9): 352-357; 2002.
  18. **Yang TS**, Wang CH, Hsieh RK, Chen JS, Fung MC. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma - a phase I-II trial. *Ann Oncol* 13:1771-1778, 2002
  19. **Yang TS**, Chen JS, Tang R, Chiang JM, Hsieh PS, Yeh CY, Changchien CR. Biweekly bolus 5-fluorouracil and leucovorin plus oxaliplatin in pretreated patients with advanced colorectal cancer: a dose-finding study. *Anti-cancer drugs* 14(2): 145-151, 2003
  20. **Yang TS**, Chen JS, Tang R, Chiang JM, Hsieh PS, Yeh CY, Changchien CR. Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study. *Cancer Chemotherapy* 2003 ;49(4):194-9.
  21. Chen JS, **Yang TS**, Lin YC, Jan YY. A phase II trial of tegafur-uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas. *Jpn J Clin Oncol*. 2003, 33(7):353-6.
  22. **Yang TS**, Chang HK, Chen JS, Lin YC, Liau CT, Chang WC M. Chemotherapy

- using 5-Fluorouracil, Mitoxantrone and Cisplatin for Patients with Advanced Hepatocellular Carcinoma: An analysis of 63 cases. *J Gastroenterol* 2004, 39(4):362-9.
23. Hsieh RK, Chao TY, Chen WS, **Yang TS**, Chen LT, Chen PM, Liu JM. Oxaliplatin added simplified bimonthly low-dose leucovorin and 5-FU for pretreated advanced colorectal cancer is effective and affected by different previous 5-FU regimen. *Cancer Invest* 2004, 22(2171-9
24. Sheen WC, Chen JS, Wang HM, **Yang TS**, Liaw CC, Lin YC. A Modified Low-dose Regimen of Mitoxantrone and Prednisolone in Patients with Androgen-independent Prostate Cancer. *Jpn J Clin Oncol*. 2004 Jun;34(6):337-41
25. Chang JWC, Yeh KY, Wang CH, **Yang TS**, Chiang HF, Wei FC, Kuo TT, Yang CH. Malignant melanoma in Taiwan: a prognostic study of 181 cases. *Melanoma Res* 2004, 14:537-541.
26. Chen JS, Huang JS, **Yang TS**, Lin YC, Wang HM, Liau CT, Rau KM. Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer. *Anticancer Drugs*. 2005 Jan;16(1):47-51
27. Lin YC, Chang HK, Chen JS, Wang HM, **Yang TS**, Liaw CC, A Phase II Randomized Study of Two Taxanes and Cisplatin for Metastatic Breast Cancer after Anthracycline: A Final Analysis. *Jpn J Clin Oncol*. 2007 Jan;37(1):23-9
28. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, **Yang TS**, Rivera F, Couture F, Sirzén F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. *J Clin Oncol*. 2008 Apr 20;26(12):2006-12
29. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, **Yang TS**, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol*. 2008 Apr 20;26(12):2013-9
30. Liaw CC, Chen JS, Chang HK, Huang JS, **Yang TS**, Liau CT. Symptoms and signs of port-related infections in oncology patients related to the offending pathogens. *Int J Clin Pract*. 2008 Aug;62(8):1193-8
31. Chen JS, Rau KM, Chen YY, Huang JS, **Yang TS**, Lin YC, Liau CT, Lee KD, Su YC, Kao RH. A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer. *Cancer Chemother Pharmacol*. 2009 Apr;63(5):819-25

32. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, **Yang TS**, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol.* 2009 Jan;10(1):25-34
33. Hsu HC, Chang HK, Lin YC, Hseu S, Chen JS, **Yang TS**, Wang HM, Shen WC. The role of HER2 in metastatic breast cancer treated with a combination of taxanes and cisplatin. *Chang Gung Med J.* 2009 Jan-Feb;32(1):33-41
34. Chen JS, Chao Y, **Yang TS**, Chou WC, Chen LT, Lee KD, Lin YC. A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma. *Cancer Chemother Pharmacol.* 2009 Dec;65(1):151-7
35. Hsu CH, **Yang TS**, Hsu C, Toh HC, Epstein RJ, Hsiao LT, Chen PJ, Lin ZZ, Chao TY, Cheng AL. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. *Br J Cancer.* 2010 Mar 16;102(6):981-6
36. **Yang TS**, Lu SN, Chao Y, Sheen IS, Lin CC, Wang TE, Chen SC, Wang JH, Liao LY, Thomson JA, Wang-Peng J, Chen PJ, Chen LT. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. *Br J Cancer.* 2010 Sep 28;103(7):954-60
37. Su PJ, Chen JS, Liaw CC, Chang HK, Wang HM, **Yang TS**, Lin YC, Liau CT, Yang HY, Yeh KY, Ho MM, Chang NJ, Wang CH, Chang JW. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma. *Chang Gung Med J.* 2011 Sep-Oct; 34(5):478-86.
38. Shen WC, **Yang TS**, Hsu HC, Chen JS. A phase II study of irinotecan in combination with cisplatin as second-line chemotherapy in patients with metastatic or locally advanced gastric cancer. *Chang Gung Med J.* 2011 Nov-Dec;34(6):590-8
39. Po-Jung Su, Chia-Hsun Hsieh, **Tsai-Sheng Yang**. Leptomeningeal Carcinomatosis from a Primary Colon Cancer Patient 台灣癌症醫誌 (J. Cancer Res. Pract.) 27(3),113-116, 2011 (Corresponding Author)
40. Wen-Kuan Huang, Tse-Ching Chen, Pao-Shiu Hsieh, Jen-Shi Chen, Chuang-Chi Liaw, Yung-Chang Lin, **Tsai-Sheng Yang**. Rapid Progression of Second Primary Hepatocellular Carcinoma in a Patient with Locally Advanced Rectal Cancer 台灣癌症醫誌 (J. Cancer Res. Pract.) 28(4),189-195, 2012 (Corresponding Author)
41. Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, **Yang TS**, Tak WY, Pan H, Yu

- S, Xu J, Fang F, Zou J, Lentini G, Voliotis D, Kang YK. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. *Eur J Cancer*. 2012 Jul;48(10):1452-65
42. Hsu C, **Yang TS**, Huo TI, Hsieh RK, Yu CW, Hwang WS, Hsieh TY, Huang WT, Chao Y, Meng R, Cheng AL. Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study. *J Hepatol*. 2012 May;56(5):1097-103
43. Huang WK, Chang JW, See LC, Tu HT, Chen JS, Liaw CC, Lin YC, **Yang TS**. Higher rate of colorectal cancer among patients with pyogenic liver abscess with Klebsiella pneumoniae than those without: an 11-year follow-up study. *Colorectal Dis*. 2012 Dec;14(12):e794-801 (Corresponding Author)
44. Hsu HC, Liu YS, Tseng KC, Hsu CL, Liang Y, **Yang TS**, Chen JS, Tang RP, Chen SJ, Chen HC. Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer. *Int J Colorectal Dis*. 2013 Jun 20
45. Huang WK, Chiou MJ, Yu KH, Lin YC, **Yang TS**, Chen JS, Kuo CF, See LC. The association between low-dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study. *Aliment Pharmacol Ther*. 2013 Aug;38(4):432-9
46. Hsu CH, Kang YK, **Yang TS**, Shun CT, Shao YY, Su WC, Sandoval-Tan J, Chiou TJ, Jin K, Hsu C, Cheng AL. Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study. *Oncology*. 2013;85(1):44-52
47. Hsu HC, Chou WC, Shen WC, Wu CE, Chen JS, Liau CT, Lin YC, **Yang TS**. Efficacy of Postoperative Oxaliplatin- or Irinotecan-based Chemotherapy After Curative Resection of Synchronous Liver Metastases from Colorectal Cancer. *Anticancer Res*. 2013 Aug;33(8):3317-25 (Corresponding Author)
48. Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, **Yang TS**, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus Doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. *J Clin Oncol*. 2013 Oct 1;31(28):3501-8
49. Huang WK, Lin YC, Chiou MJ, **Yang TS**, Chang JW, Yu KH, Kuo CF, See LC. Pyogenic Liver Abscess as a Warning Sign for Primary Liver Cancer: A Nationwide Population-based Study. *Asian Pac J Cancer Prev*. 2013;14(8):4727-4731.